# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Correction: JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1...
JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $1050 to $1...
Citigroup analyst Peter Verdult reinstates Eli Lilly (NYSE:LLY) with a Buy and announces $1060 price target.
The investment is aimed at ensuring a steady supply of the drugs, which have been grappling with shortages since 2022.
This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 202...
- Reuters